AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10677386
Drug: C-peptide infusion
RxNorm normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-peptide infusion at 3 pmol.min(‐1).kg(‐1) for 60 min and then at 10 pmol.min(‐1).kg(‐1) for 60 min
Trial: 8931848
Drug: Bunazosin retard
RxNorm normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin retard (12 mg)
Trial: 8931848
Drug: Prazosin retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin retard (4 mg)
Trial: 3893286
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment plus thymostimulin
Trial: 3893286
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment plus placebo (control group)
Trial: 31388739
Drug: Spirulina (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirulina (4.8 g daily for 17 days)
Trial: 31388739
Drug: Wakame (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wakame (4.8 g daily for 17 days)
Trial: 28002316
Drug: Oral pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pregabalin 150 mg and intravenous normal saline (group HP)
Trial: 28002316
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine 40 mg (group L)
Trial: 28002316
Drug: Oral pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pregabalin 75 mg and intravenous normal saline (group LP)
Trial: 24231639
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein intake (≥ 4.6 g · kg(‐1) · day(‐1))
Trial: 24231639
Drug: Average protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average protein intake of 4.3 ± 0.4 g · kg(‐1) · day(‐1)
Trial: 24231639
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein group (4.6 to 5.5 g · kg(‐1) · day(‐1), n = 16)
Trial: 23326930
Drug: Test treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test treatment (nutriological combination of vitamins, trace elements, and phytochemicals)
Trial: 20615100
Drug: GLIM +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLIM + PIO combination (up-titration 2 mg + 30 mg/4 mg + 30 mg/4 mg + 4 mg)
Trial: 20615100
Drug: GLIM (up-titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLIM (up-titration 4/5/6 mg)
Trial: 15723969
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 to 16 mg per day)
Trial: 15723969
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 to 20 mg per day)
Trial: 10740903
Drug: DHE focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHE focused on oral hygiene instruction (OHI) using fluoride toothpaste
Trial: 9690309
Drug: Chemotherapy containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy containing platinum
Trial: 9690309
Drug: Chemotherapy using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy using alkylating agents
Trial: 9690309
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with Cisplatin
Trial: 9690309
Drug: Concomitant radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant radiotherapy and chemotherapy using 5-Fluoro-uracil, VP16, and platinum
Trial: 9690309
Drug: Short initial
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short initial chemotherapy or concomitant therapy
Trial: 9690309
Drug: Short neoadjuvant
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short neoadjuvant chemotherapy to surgery
Trial: 2345633
Drug: Silymarin (Legalon)
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (Legalon) therapy at a daily dose of 420 mg for six months
Trial: 6303490
Drug: Cefoxitin 2
RxNorm normalized name: cefoxitin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2 g intramuscularly with oral probenecid 1 g
Trial: 26803355
Drug: Exenatide supplementation
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide supplementation on glargine insulin (group B)
Trial: 26803355
Drug: Intense, self-regulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intense, self-regulated insulin therapy alone (group C)
Trial: 22080870
Drug: Metacognitive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive therapy (MCT), 8 weekly intervention sessions
Trial: 20411995
Drug: Pharmacists provided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacists provided intensified hypertension management and drug adherence counseling
Trial: 15966377
Drug: Epidural tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural tramadol infusion
Trial: 15966377
Drug: Intravenous tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tramadol infusion
Trial: 12651051
Drug: Acute hyperglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute hyperglycemia (13.9 mmol/l, 250 mg/dl)
Trial: 12651051
Drug: Euglycemia (5.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycemia (5.5 mmol/l, 100 mg/dl)
Trial: 31491932
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + Learning (E + L)
Trial: 31491932
Drug: Learning Only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Learning Only (L)
Trial: 29174765
Drug: Attention Control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention Control Treatment (ACT)
Trial: 12446070
Drug: Algorithm combining
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm combining basal volume flow <20 ml/min and graft flow reserve <2
Trial: 10100178
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose E2/NETA (2 mg E2/1 mg NETA)
Trial: 17530099
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose E2/NETA (1 mg E2/0.5 mg NETA)
Trial: 8889353
Drug: Enalapril drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril drug regimen
Trial: 8889353
Drug: Atenolol drug
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol drug regimen
Trial: 8889353
Drug: Amlodipine drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine drug regimen
Trial: 7104149
Drug: metoprolol, 100-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol, 100-300 mg/day
Trial: 7104149
Drug: pindolol, 5-15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol, 5-15 mg/day
Trial: 30499837
Drug: Group MP
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group MP (300 mg pregabalin orally + IV magnesium sulphate 50 mg/kg)
Trial: 30499837
Drug: Group P
RxNorm normalized name: High mobility group protein HMGI-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group P (300 mg pregabalin orally + IV placebo)
Trial: 30499837
Drug: Group M
RxNorm normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group M (IV magnesium sulphate 50 mg/kg + placebo capsule)
Trial: 30499837
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (placebo capsule + IV placebo)
Trial: 30650288
Drug: Glucosamine, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucosamine, 1 pill each time, 3 times per day for 3 months
Trial: 26703477
Drug: Intra-articular facet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular facet joint injections with local anaesthetic and steroids
Trial: 20022553
Drug: ZengShengPing (ZSP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZengShengPing (ZSP) - 4 tablets, 3 times per day for 8-12 months
Trial: 18154900
Drug: Therapeutic hypothermia
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic hypothermia (head cooling for 72 hours starting within 6 hours of birth, rectal temperature maintained at 34.5 degrees C ± 0.5 degrees C)
Trial: 10531164
Drug: Manual titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual titrated nCPAP therapy
Trial: 1989572
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of oral haloperidol
Trial: 1989572
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d of oral haloperidol
Trial: 1989572
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of oral haloperidol
Trial: 6636033
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of fish oil (n-3 PUFA) for 4 weeks
Trial: 6636033
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of vegetable oil (n-6 PUFA) for 4 weeks
Trial: 30399034
Drug: CrAg screening
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CrAg screening and preemptive fluconazole therapy
Trial: 30555398
Drug: Self-help book
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-help book for insomnia (cognitive behavioral therapy for insomnia)
Trial: 25228440
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lutein
Trial: 25228440
Drug: lutein (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lutein (10 mg) + zeaxanthin (10 mg)
Trial: 19043656
Drug: Alendronate therapy
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate therapy (with calcium 500 mg/day and cholecalciferol 250 IU/day)
Trial: 11259687
Drug: Statin drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin drugs (HMG CoA reductase inhibitors)
Trial: 1977438
Drug: Cicloprolol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicloprolol 50 mg day‐1 with digoxin 0.25 mg day‐1
Trial: 1977438
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with digoxin 0.25 mg day‐1
Trial: 318680
Drug: Dextroamphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (15 mg)
Trial: 318680
Drug: L-dopa (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-dopa (125 to 500 mg)
Trial: 318680
Drug: Dextroamphetamine (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (after treatment with methylphenidate)
Trial: 318680
Drug: Methylphenidate (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (after treatment)
Trial: 23453011
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (target blood glucose 120-160 mg/dl)
Trial: 23453011
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (target blood glucose 161-200 mg/dl)
Trial: 21557031
Drug: Delivery of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delivery of influenza vaccine
Trial: 19234885
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg twice daily for 3 weeks
Trial: 12742557
Drug: Low-dose COC
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose COC (20 microg EE and 75 microg GTD) - Group A
Trial: 12742557
Drug: Ultra-low-dose COC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low-dose COC (15 microg EE and 60 microg GTD) - Group B
Trial: 8922571
Drug: Azithromycin 10
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 10 mg/kg 1 x daily for 3 days
Trial: 8922571
Drug: Azithromycin 20
RxNorm normalized name: azithromycin 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 20 mg/kg 1 x daily for 3 days
Trial: 8922571
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 125-250 mg 4 x daily for 10 days
Trial: 6690193
Drug: 99mTc‐labelled erythrocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐labelled erythrocytes (IgG‐RBC) coated with Rhesus anti‐D antibody (high coating)
Trial: 6690193
Drug: 99mTc‐labelled erythrocytes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐labelled erythrocytes (IgG‐RBC) coated with Rhesus anti‐D antibody (low coating)
Trial: 31706286
Drug: Herbal combination
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal combination (420 mg proprietary blend of Urox®)
Trial: 12077544
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole + 0.05% desonide gel (n = 9)
Trial: 12077544
Drug: Unmedicated gel
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unmedicated gel (placebo) (n = 9)
Trial: 8541695
Drug: Structured-triglyceride (STG)
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured-triglyceride (STG) emulsion (medium and high doses)
Trial: 8541695
Drug: Fat infusion
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat infusion (STG and LCT)
Trial: 31812554
Drug: Pembrolizumab at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab at an initial dose of 2 mg/kg every 3 weeks
Trial: 23379590
Drug: Lanthanum carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lanthanum carbonate (1500 mg-3000 mg)
Trial: 18036080
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg) administered every 2 hours each night for 4 administrations
Trial: 8203435
Drug: Preoperative gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative gonadotropin-releasing hormone agonist (leuprolide acetate) for 2 months
Trial: 8203435
Drug: Preoperative gonadotropin-releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative gonadotropin-releasing hormone agonist (leuprolide acetate)
Trial: 29203473
Drug: THR‐184 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THR‐184 treatment groups
Trial: 20556561
Drug: Eprosartan 600
RxNorm normalized name: eprosartan 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 600 mg + Hydrochlorothiazide 12.5 mg
Trial: 15842137
Drug: Jianpi Huoxue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jianpi Huoxue herbs (JPHXH) plus chemotherapy (CT)
Trial: 10229292
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug therapy (most commonly an ACE inhibitor)
Trial: 1751272
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg kg‐1 followed by fentanyl 2 micrograms kg‐1
Trial: 6936524
Drug: Hydrocodone-acetaminophen combination
RxNorm normalized name: Dolorex Forte (hydrocodone / acetaminophen) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone-acetaminophen combination
Trial: 6936524
Drug: Codeine-acetaminophen combination
RxNorm normalized name: acetaminophen / codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine-acetaminophen combination
Trial: 6936524
Drug: Codeine-APC combination
RxNorm normalized name: Codeine
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine-APC combination
Trial: 19541918
Drug: Individualized best
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized best conventional therapy (CONV)
Trial: 14988688
Drug: Potent, selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent, selective inhibitor of type I 5 alpha-reductase used alone
Trial: 14988688
Drug: Potent, selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potent, selective inhibitor of type I 5 alpha-reductase in combination with systemic minocycline
Trial: 10211015
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with bupivacaine (40 mg bolus followed by 15 mg h‐1 infusion)
Trial: 26571884
Drug: Acupuncture and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture and medication group (acupuncture + 20 mg fluoxetine once daily for 4 weeks)
Trial: 26571884
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (20 mg fluoxetine once daily for 4 weeks)
Trial: 17146419
Drug: food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: food supplement containing hydrolyzed sea fish cartilage, vitamin C, vitamin E, folic acid, zinc, copper (Captafer)
Trial: 17146419
Drug: food supplement
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: food supplement
Trial: 1582107
Drug: Conventional ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conventional ibuprofen tablets 600 mg QID (CI)
Trial: 1582107
Drug: Sustained-release ibuprofen
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release ibuprofen tablets 1200 mg BID (SRI)
Trial: 3973309
Drug: Oral food
RxNorm normalized name: Nutritional Supplement Oral Food, Solid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral food challenge with suspected food
Trial: 27369044
Drug: Bi-weekly emails
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly emails for first 4 weeks and then weekly emails for the next 8 weeks targeting self‐efficacy, social support, goal setting, and benefits/barriers to walking (Dog owners)
Trial: 27369044
Drug: Bi-weekly emails
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly emails for first 4 weeks and then weekly emails for the next 8 weeks targeting self‐efficacy, social support, goal setting, and benefits/barriers to walking (Non-dog owners)
Trial: 23800154
Drug: Daily dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q‐Ter for 2 months (Group A)
Trial: 21555764
Drug: Etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETR) 200 mg q12h
Trial: 21555764
Drug: Etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETR) combined with Lopinavir (LPV)/Ritonavir (RTV) 200/400/100 mg q12h
Trial: 21555764
Drug: Etravirine (ETR)
RxNorm normalized name: Etravirine
DrugBank: Etravirine (DB06414)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Etravirine (ETR) combined with Darunavir (DRV)/Ritonavir (RTV) 200/600/100 mg q12h
Trial: 19327739
Drug: Intraoperative sub-Tenon
RxNorm normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative sub-Tenon injection of triamcinolone acetonide (TA)
Trial: 19327739
Drug: No intraoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intraoperative sub-Tenon injection of triamcinolone acetonide (TA)
Trial: 17576909
Drug: Antiviral plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral plus steroid therapy
Trial: 9556926
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of antibodies against Trypanosoma cruzi using a commercial ELISA kit
Trial: 8052870
Drug: Carboplatin/etoposide chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin/etoposide chemotherapy and thoracic irradiation
Trial: 8052870
Drug: Cisplatin/etoposide chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/etoposide chemotherapy and thoracic irradiation
Trial: 28870191
Drug: Translatory dorsal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Translatory dorsal glide mobilization (TDGM) C0‐C1 technique, adjunct to protocolized physiotherapy treatment
Trial: 28870191
Drug: Pressure maintained
RxNorm normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pressure maintained suboccipital inhibition technique (PMSIT), adjunct to protocolized physiotherapy treatment